logo-loader
viewKape Technologies PLC

Kape turns privacy crusader with purchase of VPN provider PIA

The acquisition is expected to double Kape’s paying subscribers and increase 2020 earnings by 90%

Kape Technologies PLC - Kape Technologies to buy Private Internet Access’ owner
PIA is a major VPN service provider

Kape Technologies PLC’s (LON:KAPE) shares flew higher as the company was poised to double its subscribers by acquiring the owner of virtual private network (VPN) operator Private Internet Access (PIA) for US$95.5mln.

The acquisition of the US-based digital privacy specialist will bring more than 1mln paying customers, with high retention rates, which will double the London-listed security software firm’s client base.

Kape, which will adopt the PIA name on completion, said it expects the addition to boost its 2020 earnings by 90%, with predicted annual cost synergies of between US$3.5mln and US$4.5mln a year after completion, which is pencilled in for early 2020.

“The acquisition has immediate and important benefits – doubling Kape’s customer base from day one, to over 2mln paying subscribers globally, with almost half based in the US, and positioning the group as a global leader within the fast-growing digital privacy sector,” analysts at house broker Shore Capital said in a note.

Shares in Kape were up 34% to 103.51p on Tuesday morning.

Quick facts: Kape Technologies PLC

Price: 162 GBX

LSE:KAPE
Market: LSE
Market Cap: £240.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' ...

The Life Sciences Division's Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals. Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.

7 minutes ago

2 min read